TaiMed Biologics Inc. (4147) Stock Statistics & Valuation Metrics
Total Valuation
TaiMed Biologics Inc. has a market cap or net worth of TWD 15.03B. The enterprise value is TWD 12.85B.
- Market Cap
- TWD 15.03B
- Enterprise Value
- TWD 12.85B
Share Statistics
TaiMed Biologics Inc. has 273,202,420 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 273,202,420
- Owned by Insiders
- ―
- Owned by Institutions
- 2.35%
Financial Efficiency
TaiMed Biologics Inc.’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is -4.24%.
- Return on Equity (ROE)
- -0.04
- Return on Assets (ROA)
- -0.03
- Return on Invested Capital (ROIC)
- -4.24%
- Return on Capital Employed (ROCE)
- -0.04
- Revenue Per Employee
- 765.14K
- Profits Per Employee
- -209.98K
- Employee Count
- 799
- Asset Turnover
- 0.13
- Inventory Turnover
- 0.25
Valuation Ratios
The current PE Ratio of TaiMed Biologics Inc. is -122.55. TaiMed Biologics Inc.’s PEG ratio is -2.34.
- PE Ratio
- -122.55
- PS Ratio
- 27.31
- PB Ratio
- 4.58
- Price to FCF
- 156.79
- Price to Operating Cash Flow
- 108.58
- PEG Ratio
- -2.34
Income Statement
In the last 12 months, TaiMed Biologics Inc. had revenue of 611.35M and earned -167.78M in profits. Earnings per share was -0.61.
- Revenue
- 611.35M
- Gross Profit
- 259.45M
- Operating Income
- -194.65M
- Pretax Income
- -167.78M
- Net Income
- -167.78M
- EBITDA
- -41.66M
- Earnings Per Share (EPS)
- -0.61
Cash Flow
In the last 12 months, operating cash flow was 155.12M and capital expenditures -47.21M, giving a free cash flow of 107.91M billion.
- Operating Cash Flow
- 155.12M
- Free Cash Flow
- 107.91M
- Free Cash Flow per Share
- 0.40
Dividends & Yields
TaiMed Biologics Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.66%
- Earnings Yield
- -0.85%
Stock Price Statistics
- Beta
- 0.30
- 52-Week Price Change
- -19.47%
- 50-Day Moving Average
- 61.04
- 200-Day Moving Average
- 57.26
- Relative Strength Index (RSI)
- 33.21
- Average Volume (3m)
- 1.00M
Important Dates
TaiMed Biologics Inc. upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- May 07, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
TaiMed Biologics Inc. as a current ratio of 13.11, with Debt / Equity ratio of 12.78%
- Current Ratio
- 13.11
- Quick Ratio
- 7.59
- Debt to Market Cap
- 0.03
- Net Debt to EBITDA
- 9.73
- Interest Coverage Ratio
- -18.17
Taxes
In the past 12 months, TaiMed Biologics Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
TaiMed Biologics Inc. EV to EBITDA ratio is -909.15, with an EV/FCF ratio of 146.97.
- EV to Sales
- 25.60
- EV to EBITDA
- -909.15
- EV to Free Cash Flow
- 146.97
- EV to Operating Cash Flow
- 102.24
Balance Sheet
TaiMed Biologics Inc. has TWD 1.61B in cash and marketable securities with TWD 478.14M in debt, giving a net cash position of TWD 1.13B billion.
- Cash & Marketable Securities
- TWD 1.61B
- Total Debt
- TWD 478.14M
- Net Cash
- TWD 1.13B
- Net Cash Per Share
- TWD 4.13
- Tangible Book Value Per Share
- TWD 12.18
Margins
Gross margin is 45.77%, with operating margin of -30.27%, and net profit margin of -22.42%.
- Gross Margin
- 45.77%
- Operating Margin
- -30.27%
- Pretax Margin
- -22.42%
- Net Profit Margin
- -22.42%
- EBITDA Margin
- -2.82%
- EBIT Margin
- -27.63%
Analyst Forecast
The average price target for TaiMed Biologics Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 3.58%
- EPS Growth Forecast
- 43.12%
